📣 VC round data is live. Check it out!
- Public Comps
- Sino Biological
Sino Biological Valuation Multiples
Discover Sino Biological's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Shanghai Medicilon, Porton Pharma Solutions, Evotec, Aurisco Pharmaceutical and more.
Sino Biological Overview
About Sino Biological
Sino Biological Inc is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones.
Founded
2016
HQ

Employees
N/A
Website
Financials (FY)
EV
$671M
Valuation Multiples
Start free trialSino Biological Financials
Sino Biological reported last fiscal year revenue of $103M and EBITDA of $40M.
In the same fiscal year, Sino Biological generated $76M in gross profit, $40M in EBITDA, and $22M in net income.
Revenue (LTM)
Sino Biological P&L
In the most recent fiscal year, Sino Biological reported revenue of $103M and EBITDA of $40M.
Sino Biological is profitable as of last fiscal year, with gross margin of 73%, EBITDA margin of 39%, and net margin of 21%.
Financial data powered by Morningstar, Inc.
Sino Biological Stock Performance
Sino Biological has current market cap of $1B, and enterprise value of $671M.
Market Cap Evolution
Sino Biological's stock price is $9.41.
Sino Biological share price increased by 0.9% in the last 30 days, and decreased by 4.8% in the last year.
Sino Biological has an EPS (earnings per share) of $0.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $671M | $1B | 0.9% | 0.9% | -9.5% | -4.8% | $0.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSino Biological Valuation Multiples
Sino Biological trades at 6.5x EV/Revenue multiple, and 16.6x EV/EBITDA.
EV / Revenue (LTM)
Sino Biological Financial Valuation Multiples
As of June 2, 2026, Sino Biological has market cap of $1B and EV of $671M.
Sino Biological has a P/E ratio of 52.4x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sino Biological Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Sino Biological Margins & Growth Rates
In the most recent fiscal year, Sino Biological reported gross margin of 73%, EBITDA margin of 39%, and net margin of 21%.
Sino Biological Margins
Sino Biological Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Sino Biological Operational KPIs
Data powered by FactSet, Inc. and Morningstar, Inc.
Sino Biological Competitors
Sino Biological competitors include Shanghai Medicilon, Porton Pharma Solutions, Evotec, Aurisco Pharmaceutical, Oxford BioMedica, ACROBiosystems, Gubra, Sirio Pharma Co, Bora Pharmaceuticals and Akums Drugs and Pharma.
Most Sino Biological public comparables operate across Contract Research & Manufacturing, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 6.5x | 6.0x | (116.9x) | - | |||
| 2.4x | 2.3x | 12.0x | 11.6x | |||
| 1.1x | 1.1x | 20.9x | 32.2x | |||
| 4.8x | 4.6x | 12.1x | 11.3x | |||
| 4.8x | 4.2x | 336.1x | 72.8x | |||
| 6.5x | 5.9x | 22.8x | 21.1x | |||
| 1.8x | 2.7x | 2.2x | 3.8x | |||
| 1.6x | 1.6x | 12.6x | 10.8x | |||
This data is available for Pro users. Sign up to see all Sino Biological competitors and their valuation data. Start Free Trial | ||||||
Sino Biological VC Funding History
Before going public, Sino Biological raised $45M in total equity funding, across 2 rounds.
Sino Biological Funding Rounds
Acquisitions by Sino Biological
Sino Biological has acquired 1 company to date.
Last acquisition by Sino Biological was on April 26th 2024. Sino Biological acquired SignalChem for $48M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Sino Biological
| Description | SignalChem is a biotechnology company producing recombinant proteins for cell signaling research and drug discovery. Based in Richmond, British Columbia, Canada, the firm manufactures highly purified human proteins subjected to stringent quality controls, serving academic and biotech customers in kinase, phosphatase, and ubiquitin-related studies. |
| HQ Country | |
| HQ City | - |
| Deal Date | 26 Apr 2024 |
| Valuation | $48M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Sino Biological acquisitions and their M&A valuation multiples. Start Free Trial | |
Investments by Sino Biological
Sino Biological has invested in 1 company to date.
Latest investment by Sino Biological was on February 2nd 2023. Sino Biological invested in PhaBuilder in their $53M Series A round (EV/Revenue multiple available to Pro users).
Latest Investments by Sino Biological
| Description | PhaBuilder is a synthetic biology firm engineering halophilic microbes for industrial applications through next-generation biotechnology. It produces biodegradable PHA polymers, ectoine as a pharmaceutical intermediate, and cadaverine for Nylon 56 precursors. Based in Beijing at the China-Germany Industrial Park, PhaBuilder develops products in its synthetic biology facility and constructs a PHA production plant in Yichang, Hubei Province. The company expands with additional large-scale bases across China. | PhaBuilder is a synthetic biology firm engineering halophilic microbes for industrial applications through next-generation biotechnology. It produces biodegradable PHA polymers, ectoine as a pharmaceutical intermediate, and cadaverine for Nylon 56 precursors. Based in Beijing at the China-Germany Industrial Park, PhaBuilder develops products in its synthetic biology facility and constructs a PHA production plant in Yichang, Hubei Province. The company expands with additional large-scale bases across China. |
| HQ Country | ||
| HQ City | Beijing | Beijing |
| Deal Date | 2 Feb 2023 | 4 Nov 2022 |
| Round | Series A | Series A |
| Raised | $53M | $13M |
| Investors | Agricultural Fund of China; Chengtong Mixed Reform; FTZ Fund; Fuhua Capital; HSG; Kunlun Trust; Lingang Science and Technology Innovation; Sino Biological; Zhonghai Investment | Sino Biological |
| Valuation | $287M | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Sino Biological investments and their VC round multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sino Biological
| When was Sino Biological founded? | Sino Biological was founded in 2016. |
| Where is Sino Biological headquartered? | Sino Biological is headquartered in China. |
| Is Sino Biological publicly listed? | Yes, Sino Biological is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Sino Biological? | Sino Biological trades under 301047 ticker. |
| When did Sino Biological go public? | Sino Biological went public in 2021. |
| Who are competitors of Sino Biological? | Sino Biological main competitors include Shanghai Medicilon, Porton Pharma Solutions, Evotec, Aurisco Pharmaceutical, Oxford BioMedica, ACROBiosystems, Gubra, Sirio Pharma Co, Bora Pharmaceuticals, Akums Drugs and Pharma. |
| What is the current market cap of Sino Biological? | Sino Biological's current market cap is $1B. |
| What is the current revenue of Sino Biological? | Sino Biological's last fiscal year revenue is $103M. |
| What is the current EV/Revenue multiple of Sino Biological? | Current revenue multiple of Sino Biological is 6.5x. |
| Is Sino Biological profitable? | No, Sino Biological is not profitable. |
| How many companies Sino Biological has acquired to date? | As of June 2026, Sino Biological has acquired 1 company. |
| What was the largest acquisition by Sino Biological? | $48M acquisition of SignalChem on 26th April 2024 was the largest M&A Sino Biological has done to date. |
| What companies Sino Biological acquired? | Sino Biological acquired SignalChem. |
| In how many companies Sino Biological has invested to date? | As of June 2026, Sino Biological has invested in 1 company. |
| What was the last Sino Biological investment? | On 2nd February 2023 Sino Biological invested in PhaBuilder, participating in a $53M Series A round at $287M valuation, alongside Agricultural Fund of China, Chengtong Mixed Reform, FTZ Fund, Fuhua Capital, HSG, Kunlun Trust, Lingang Science and Technology Innovation, and Zhonghai Investment. |
| In what companies Sino Biological invested in? | Sino Biological invested in PhaBuilder. |
See public comps similar to Sino Biological
Lists including Sino Biological
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

